A Phase 1 interventional study of Saxagliptin and Metformin IR (glucophage) in Type 2 Diabetes Mellitus, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 19 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-05-21.
Sponsored by AstraZeneca · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 74 studies testing saxagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. saxagliptin · Diabetes Mellitus, Type 2.
Among the 74 studies testing saxagliptin in Diabetes Mellitus, Type 2, this one is the 59th largest by enrollment, is one of 10 that started in 2009, is one of 14 in phase 1, and was the 15th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →1 of the 74 studies testing saxagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
saxagliptin: first FDA approval 2009 (ONGLYZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 19 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
74 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 4 · Phase 3 28 · Phase 4 25
First in 2003; this study’s year is marked. 10 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 138 across the 74 interventional studies. Of the 64 that completed or were terminated, 47 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 74 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
345 studies in Diabetes Mellitus, Type 2 by AstraZeneca: 13 open now, 15 under way, 9 of them phase 3. Of 325 finished, 149 (46%) have results posted.
Among the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, this one is the 239th largest by enrollment of the 280 interventional ones that give a count, is one of 43 that started in 2009, is one of 86 in phase 1, and was the 122nd registered.
AstraZeneca’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing saxagliptin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
Add it to your calendar (.ics) → With an account.
Among the 74 studies testing saxagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 345 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
To demonstrate bioequivalence of a 2.5 mg saxagliptin/1000 mg metformin (glucophage) immediate release (IR) fixed dose combination (FDC) tablet to the 2.5 mg saxagliptin tablet and 1000 mg metformin IR tablet co-administered to healthy subjects in a fasted and in a fed state.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Co-administration of single oral doses of a 2.5 mg tablet of saxagliptin and a 1000 mg tablet of metformin IR under fasted conditions
Drug: Saxagliptin · Drug: Metformin IR (glucophage)
Single oral dose of a FDC tablet consisting of 2.5 mg saxagliptin/ 1000 mg metformin IR under fasted conditions
Drug: Saxagliptin + Metformin IR (FDC)
Co-administration of single oral doses of a 2.5 mg tablet of saxagliptin and a 1000 mg tablet of metformin IR under fed conditions with a standard meal
Drug: Saxagliptin · Drug: Metformin IR (glucophage)
Single oral dose of a FDC tablet consisting of 2.5 mg saxagliptin/ 1000 mg metformin IR under fed conditions with a standard meal
Drug: Saxagliptin + Metformin IR (FDC)
Tablet, Oral, 2.5 mg, Once Daily, 1 week
Also known as: Onglyza
Tablets, Oral, 1000 mg, Once Daily, 1 week
Also known as: Glucophage
Drug pages: Saxagliptin · Metformin
Tablet, Oral, Saxagliptin 2.5 mg + metformin IR 1000 mg, Once Daily, 1 Week
Also known as: Onglyza, Glucophage
Saxagliptin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC[INF])
Single-dose PK parameters of saxagliptin were derived from plasma concentration versus time data.
Time frame: pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period
Saxagliptin PK Parameter Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Plasma Concentration (AUC[0-T])
Single-dose PK parameters of saxagliptin were derived from plasma concentration versus time data.
Time frame: pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period
Saxagliptin PK Parameter Maximum Observed Plasma Concentration (Cmax)
Single-dose PK parameters of saxagliptin were derived from plasma concentration versus time data.
Time frame: pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period
Saxagliptin PK Parameter Plasma Terminal Half-life (T-HALF)
Single-dose PK parameters of saxagliptin were derived from plasma concentration versus time data.
Time frame: pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period
Saxagliptin PK Parameter Time of Maximum Observed Plasma Concentration (Tmax)
Single-dose PK parameters of saxagliptin were derived from plasma concentration versus time data.
Time frame: pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period
Metformin PK Parameter AUC(INF)
Single-dose PK parameters of metformin were derived from plasma concentration versus time data.
Time frame: pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period
Metformin PK Parameter AUC(0-T)
Single-dose PK parameters of metformin were derived from plasma concentration versus time data.
Time frame: pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period
Metformin PK Parameter Cmax
Single-dose PK parameters of metformin were derived from plasma concentration versus time data.
Time frame: pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period
Metformin PK Parameter T-HALF
Single-dose PK parameters of metformin were derived from plasma concentration versus time data.
Time frame: pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period
Metformin PK Parameter Tmax
Single-dose PK parameters of metformin were derived from plasma concentration versus time data.
Time frame: pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period
BMS-510849 PK Parameter AUC(INF)
Single-dose PK parameters of the active metabolite of saxagliptin, BMS-510849, were derived from plasma concentration versus time data.
Time frame: pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period
BMS-510849 PK Parameter AUC(0-T)
Single-dose PK parameters of the active metabolite of saxagliptin, BMS-510849, were derived from plasma concentration versus time data.
Time frame: pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period
BMS-510849 PK Parameter Cmax
Single-dose PK parameters of the active metabolite of saxagliptin, BMS-510849, were derived from plasma concentration versus time data.
Time frame: pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period
BMS-510849 PK Parameter T-Half
Single-dose PK parameters of the active metabolite of saxagliptin, BMS-510849, were derived from their respective plasma concentration versus time data.
Time frame: pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period
BMS-510849 PK Parameter T-Max
Single-dose PK parameters of the active metabolite of saxagliptin, BMS-510849, were derived from plasma concentration versus time data.
Time frame: pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period
Deaths, Serious Adverse Events (SAEs), Adverse Events (AEs), and Discontinuations Due to AEs
An AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a patient or clinical investigation subject administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.
Time frame: AEs collected from Day 1/Period 1 through study discharge (study duration: approximately 45 days). SAEs collected from date of written consent until 30 days post discontinuation of dosing or subject's participation in the study.
AEs of Special Interest
See Outcome Measure 16 for a definition of AEs. AEs of clinical interest for saxagliptin were defined as those relating to the following:skin disorders, infection-related AEs (system organ class \[SOC\]: Infections and Infestations), thrombocytopenia, lymphopenia, hypoglycemia, cardiovascular AEs indicative of acute cardiovascular events, localized edema, fractures, pancreatitis, and AEs of hypersensitivity.
Time frame: AEs collected from Day 1/Period 1 through study discharge (study duration: approximately 45 days).
Number of Participants With Marked Laboratory Abnormalities (MA)
Laboratory abnormalities=any result that is clinically significant, met the definition of an SAE, required discontinuation or interruption of study drug, or required specific corrective therapy. Upper normal (UN)/lower normal (LN) values: leukocytes UN, 11.40x10\^3 c/uL; absolute neutrophils/bands LN, 1.500x10\^3 c/uL; aspartate aminotransferase UN, 48 U/L; alanine aminotransferase UN, 67 U/L; blood urea nitrogen UN, 20.0 mg/dL; creatine kinase UN, 350 U/L; lactate dehydrogenase UN, 249 U/L.
Time frame: Within 21 days of study Day 1, Days 1-3 of Periods 1, 2, 3, and 4.
Number of Participants With Marked Urinalysis Abnormalities
Protein, Urine Abnormality: if value \>= 2+ (or if pretreatment value \>= 1+, then \>= 2 \* pretreatment). Glucose, Urine Abnormality: if value \>= 2+ (or if pretreatment value \>= 1+, then \>= 2 \* pretreatment). Blood, Urine Abnormality: if value \>= 2+ (or if pretreatment value \>= 1+, then \>= 2 \* pretreatment). White Blood Cell (WBC), Urine Abnormality: if value \>= 2+ (or if pretreatment value \>= 2+, then \>= 4+). Red Blood Cell (RBC), Urine Abnormality: if value \>= 2+ (or if pretreatment value \>= 2+, then \>= 4+). (The '+' is a normal lab result and refers to the magnitude of the finding.)
Time frame: Within 21 days of study Day 1, Days 1-3 of Periods 1, 2, 3, and 4.
Electrocardiogram (ECG), Vital Sign, and Physical Finding Abnormalities
12-lead Electrocardiogram (ECG), Vital Sign (body temperature, respiratory rate, seated blood pressure and heart rate), and Physical Finding Abnormalities reported by investigator as AEs.
Time frame: At Screening (within 21 days of Study Day 1), Day -1 of Period 1 (ECG and Physical only), Day 1 of Periods 1-4 (Vitals only), at Study Discharge (Day 3 of Period 4) or Discontinuation
| Milestone | All Treated Participants |
|---|---|
| Started | 24 |
| Completed | 18 |
| Not completed | 6 |
| Withdrew: Adverse event | 2 |
| Withdrew: No longer met study criteria | 1 |
| Withdrew: Personal reasons | 1 |
| Withdrew: Did not return for the clinic visit | 2 |
Single-dose PK parameters of saxagliptin were derived from plasma concentration versus time data.
| ng*h/mL | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fasted | FDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fed | FDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed |
|---|---|---|---|---|
| Saxagliptin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC[INF]) | 47.25 (30.6 to 66.0) | 48.91 (28.7 to 80.7) | 52.89 (37.4 to 75.1) | 51.11 (34.2 to 73.7) |
Single-dose PK parameters of the active metabolite of saxagliptin, BMS-510849, were derived from plasma concentration versus time data.
| ng*h/mL | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fasted | FDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fed | FDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed |
|---|---|---|---|---|
| BMS-510849 PK Parameter AUC(INF) | 118.54 (58.7 to 174.4) | 116.19 (48.5 to 212.4) | 127.67 (62.5 to 217.8) | 127.25 (59.4 to 219.3) |
Single-dose PK parameters of saxagliptin were derived from plasma concentration versus time data.
| ng*h/mL | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fasted | FDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fed | FDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed |
|---|---|---|---|---|
| Saxagliptin PK Parameter Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Plasma Concentration (AUC[0-T]) | 44.90 (29.1 to 64.3) | 46.57 (27.8 to 77.7) | 50.50 (35.6 to 73.2) | 49.09 (33.5 to 71.3) |
Single-dose PK parameters of saxagliptin were derived from plasma concentration versus time data.
| ng/mL | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fasted | FDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fed | FDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed |
|---|---|---|---|---|
| Saxagliptin PK Parameter Maximum Observed Plasma Concentration (Cmax) | 8.58 (5.2 to 15.5) | 9.09 (5.5 to 17.1) | 10.97 (7.6 to 18.2) | 10.80 (7.4 to 15.9) |
Single-dose PK parameters of saxagliptin were derived from plasma concentration versus time data.
| hours | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fasted | FDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fed | FDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed |
|---|---|---|---|---|
| Saxagliptin PK Parameter Plasma Terminal Half-life (T-HALF) | 6.66 ± 1.185 | 6.34 ± 0.941 | 6.47 ± 1.529 | 5.78 ± 1.333 |
Single-dose PK parameters of saxagliptin were derived from plasma concentration versus time data.
| hours | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fasted | FDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fed | FDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed |
|---|---|---|---|---|
| Saxagliptin PK Parameter Time of Maximum Observed Plasma Concentration (Tmax) | 1.50 (0.5 to 4.0) | 0.75 (0.3 to 3.0) | 1.00 (0.3 to 3.0) | 1.50 (0.3 to 3.0) |
Single-dose PK parameters of metformin were derived from plasma concentration versus time data.
| ng*h/mL | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fasted | FDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fed | FDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed |
|---|---|---|---|---|
| Metformin PK Parameter AUC(INF) | 13363.46 (8872.9 to 19164.2) | 12677.92 (8827.3 to 16811.6) | 12357.87 (6875.3 to 15926.2) | 12126.19 (7328.6 to 15424.7) |
Single-dose PK parameters of metformin were derived from plasma concentration versus time data.
| ng*h/mL | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fasted | FDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fed | FDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed |
|---|---|---|---|---|
| Metformin PK Parameter AUC(0-T) | 13238.43 (8782.0 to 18991.8) | 12400.41 (8105.3 to 16603.8) | 12124.31 (6629.2 to 15842.4) | 11996.88 (7142.5 to 15326.6) |
Single-dose PK parameters of metformin were derived from plasma concentration versus time data.
| ng/mL | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fasted | FDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fed | FDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed |
|---|---|---|---|---|
| Metformin PK Parameter Cmax | 2004.99 (1187.2 to 3144.6) | 1830.76 (1142.5 to 2662.5) | 1666.55 (768.7 to 2256.5) | 1642.90 (848.1 to 2018.3) |
Single-dose PK parameters of metformin were derived from plasma concentration versus time data.
| hours | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fasted | FDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fed | FDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed |
|---|---|---|---|---|
| Metformin PK Parameter T-HALF | 8.43 ± 2.956 | 10.58 ± 8.895 | 11.78 ± 5.999 | 7.63 ± 2.309 |
Single-dose PK parameters of metformin were derived from plasma concentration versus time data.
| hours | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fasted | FDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fed | FDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed |
|---|---|---|---|---|
| Metformin PK Parameter Tmax | 2.00 (1.0 to 4.0) | 2.98 (1.5 to 4.0) | 4.00 (2.0 to 4.0) | 4.00 (3.0 to 4.0) |
Single-dose PK parameters of the active metabolite of saxagliptin, BMS-510849, were derived from plasma concentration versus time data.
| ng*h/mL | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fasted | FDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fed | FDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed |
|---|---|---|---|---|
| BMS-510849 PK Parameter AUC(0-T) | 108.31 (52.0 to 169.2) | 106.11 (42.3 to 201.4) | 117.42 (54.3 to 210.7) | 117.43 (51.1 to 210.9) |
Single-dose PK parameters of the active metabolite of saxagliptin, BMS-510849, were derived from plasma concentration versus time data.
| ng/mL | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fasted | FDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fed | FDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed |
|---|---|---|---|---|
| BMS-510849 PK Parameter Cmax | 16.77 (6.4 to 32.8) | 15.17 (4.7 to 32.0) | 18.24 (7.6 to 36.5) | 18.58 (6.2 to 33.5) |
Single-dose PK parameters of the active metabolite of saxagliptin, BMS-510849, were derived from their respective plasma concentration versus time data.
| hours | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fasted | FDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fed | FDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed |
|---|---|---|---|---|
| BMS-510849 PK Parameter T-Half | 8.05 ± 1.427 | 7.31 ± 1.369 | 7.48 ± 1.504 | 7.35 ± 1.622 |
Single-dose PK parameters of the active metabolite of saxagliptin, BMS-510849, were derived from plasma concentration versus time data.
| hours | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fasted | FDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fed | FDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed |
|---|---|---|---|---|
| BMS-510849 PK Parameter T-Max | 2.00 (1.0 to 4.0) | 2.00 (0.8 to 4.0) | 2.00 (1.0 to 4.0) | 2.00 (1.0 to 4.0) |
An AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a patient or clinical investigation subject administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.
| participants | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fasted | FDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fed | FDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed |
|---|---|---|---|---|
| Deaths | 0 | 0 | 0 | 0 |
| SAEs | 0 | 0 | 0 | 0 |
| AEs | 5 | 2 | 4 | 3 |
| Discontinuations dues to AEs | 0 | 0 | 1 | 1 |
See Outcome Measure 16 for a definition of AEs. AEs of clinical interest for saxagliptin were defined as those relating to the following:skin disorders, infection-related AEs (system organ class \[SOC\]: Infections and Infestations), thrombocytopenia, lymphopenia, hypoglycemia, cardiovascular AEs indicative of acute cardiovascular events, localized edema, fractures, pancreatitis, and AEs of hypersensitivity.
| participants | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fasted | FDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fed | FDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed |
|---|---|---|---|---|
| AEs of Special Interest | 0 | 0 | 0 | 0 |
Laboratory abnormalities=any result that is clinically significant, met the definition of an SAE, required discontinuation or interruption of study drug, or required specific corrective therapy. Upper normal (UN)/lower normal (LN) values: leukocytes UN, 11.40x10\^3 c/uL; absolute neutrophils/bands LN, 1.500x10\^3 c/uL; aspartate aminotransferase UN, 48 U/L; alanine aminotransferase UN, 67 U/L; blood urea nitrogen UN, 20.0 mg/dL; creatine kinase UN, 350 U/L; lactate dehydrogenase UN, 249 U/L.
| participants | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fasted | FDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fed | FDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed |
|---|---|---|---|---|
| Leukocytes - High(>1.2 * upper limit normal [ULN]) | 0 | 0 | 0 | 1 |
| Abs. Neutrophils/Bands-Low (<=lower LN [LLN]) | 1 | 1 | 1 | 1 |
| Aspartate Aminotransferase - High (>1.25 * ULN) | 0 | 0 | 0 | 1 |
| Alanine Aminotransferase - High (>1.25 * ULN) | 0 | 0 | 0 | 1 |
| Blood Urea Nitrogen - High (1.1 * ULN) | 0 | 1 | 1 | 0 |
| Creatine Kinase - High (>1.5 ULN) | 1 | 1 | 0 | 2 |
| Lactate Dehydrogenase - High (>1.25 ULN) | 0 | 0 | 0 | 1 |
Protein, Urine Abnormality: if value \>= 2+ (or if pretreatment value \>= 1+, then \>= 2 \* pretreatment). Glucose, Urine Abnormality: if value \>= 2+ (or if pretreatment value \>= 1+, then \>= 2 \* pretreatment). Blood, Urine Abnormality: if value \>= 2+ (or if pretreatment value \>= 1+, then \>= 2 \* pretreatment). White Blood Cell (WBC), Urine Abnormality: if value \>= 2+ (or if pretreatment value \>= 2+, then \>= 4+). Red Blood Cell (RBC), Urine Abnormality: if value \>= 2+ (or if pretreatment value \>= 2+, then \>= 4+). (The '+' is a normal lab result and refers to the magnitude of the finding.)
| participants | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fasted | FDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fed | FDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed |
|---|---|---|---|---|
| Protein, Urine (n=19, 19, 20, 21) | 0 | 0 | 0 | 0 |
| Glucose, Urine (n=19, 19, 20, 21) | 0 | 0 | 0 | 0 |
| Blood, Urine (n=19, 19, 20, 21) | 1 | 0 | 0 | 2 |
| White Blood Cells, Urine (n=2, 2, 2, 2) | 0 | 0 | 1 | 0 |
| Red Blood Cells, Urine (n=2, 2, 2, 2) | 0 | 0 | 0 | 0 |
12-lead Electrocardiogram (ECG), Vital Sign (body temperature, respiratory rate, seated blood pressure and heart rate), and Physical Finding Abnormalities reported by investigator as AEs.
| participants | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fasted | FDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fed | FDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed |
|---|---|---|---|---|
| ECG Abnormalities | 0 | 0 | 0 | 0 |
| Vital Sign Abnormalities | 0 | 0 | 0 | 0 |
| Physical Finding Abnormalities | 0 | 0 | 0 | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fasted | — | 0/19 (0%) | 3/19 (15.8%) |
| FDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted | — | 0/19 (0%) | 2/19 (10.5%) |
| 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fed | — | 0/21 (0%) | 2/21 (9.5%) |
| FDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed | — | 0/24 (0%) | 3/24 (12.5%) |
| Not Dosed | — | 0/34 (0%) | 0/34 (0%) |
| Event | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fasted | FDC Tablet 2.5-mg Saxa/1000-mg Met Tablet, Fasted | 2.5-mg Saxa Tablet/1000-mg Met Tablet, Fed | FDC Tablet of 2.5-mg Saxa/1000-mg Met Tablet, Fed | Not Dosed |
|---|---|---|---|---|---|
| HEADACHENervous system disorders | 1/6 | 2/6 | 2/6 | 1/6 | 0/34 |
| DIARRHOEAGastrointestinal disorders | 0/6 | 0/6 | 1/6 | 2/6 | 0/34 |
| EYE DISCHARGEEye disorders | 0/6 | 0/6 | 1/6 | 0/6 | 0/34 |
| ALANINE AMINOTRANSFERASE INCREASEDInvestigations | 1/6 | 0/6 | 0/6 | 0/6 | 0/34 |
| ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations | 1/6 | 0/6 | 0/6 | 0/6 | 0/34 |
| BLOOD LACTATE DEHYDROGENASE INCREASEDInvestigations | 1/6 | 0/6 | 0/6 | 0/6 | 0/34 |
| BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations | 1/6 | 0/6 | 0/6 | 0/6 | 0/34 |
| PALPITATIONSCardiac disorders | 0/6 | 1/6 | 0/6 | 0/6 | 0/34 |
| DIZZINESSNervous system disorders | 0/6 | 1/6 | 0/6 | 0/6 | 0/34 |
| NAUSEAGastrointestinal disorders | 1/6 | 0/6 | 1/6 | 0/6 | 0/34 |
| Age, Continuous(years) | All Enrolled and Treated Participants |
|---|---|
| Mean | 30 ± 6 |
| Sex: Female, Male(Participants) | All Enrolled and Treated Participants |
|---|---|
| Female | 8 |
| Male | 16 |
| Race/Ethnicity, Customized(participants) | All Enrolled and Treated Participants |
|---|---|
| White | 20 |
| Black | 4 |
| Body Mass Index(kg/m^2) | All Enrolled and Treated Participants |
|---|---|
| Mean | 26.5 ± 3.8 |
| weight(kg) | All Enrolled and Treated Participants |
|---|---|
| Mean | 79.9 ± 15.0 |
The record gives a start of Jun 2009, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2011, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Saxagliptin · Metformin